CD19 and AL amyloidosis: To date, the attempt to optimize CAR-NK-92 approaches is currently under evaluation in several clinical trials that include CAR-modified NK-92 for HER-2 targeting in glioblastoma (NCT03383978), BCMA targeting in multiple myeloma (NCT03940833), and CD19 targeting in CD19+ leukemia and lymphoma (NCT02892695).